IL6 and prostate carcinoma: Indeed, IL-6 and IDO have been linked to poor treatment outcomes, tumor recurrence, and aggressive tumor progression in breast cancer (49), nasopharyngeal carcinoma (50), and prostate cancer (51) patients.